New Treatment Approaches and Prognostic Biomarkers for Advanced Chronic Obstructive Pulmonary Disease and Potential Associated Cardiovascular Risks.
New Treatment Approaches and Prognostic Biomarkers for Advanced Chronic Obstructive Pulmonary Disease and Potential Associated Cardiovascular Risks.
复制标题
晚期慢性阻塞性肺疾病和潜在相关心血管风险的新治疗方法和预后生物标志物。
DOI:
10.1164/rccm.201804-0659rr
复制
发表时间:
2019
影响因子:
24.7
通讯作者:
Sankari,Abdulghani
中科院分区:
文献类型:
--
作者:
Khorfan,Omar;Alsamman,Samer;Abbas,Hawazin;Sankari,Abdulghani
Chronic obstructive pulmonary disease (COPD) has been traditionally characterized by increased concentrations of neutrophils, macrophages, proteases, IL-6 and-8, and T-helper cell type 1 cytokines, whereas asthma has been characterized by increased concentrations of eosinophils and T-helper cell type 2 cytokines (1). This paradigm has shifted in recent years, and COPD and asthma are now viewed as heterogeneous with respect to symptoms, physiology, and response to treatments. This has driven investigators to identify subpopulations of patients with specific phenotypes for which treatment can be tailored. The ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study reported that in COPD, sputum neutrophil concentrations were weakly associated with lung function and health status but not associated with exacerbations, emphysema, or systemic inflammation (2). Other COPD studies have reported that increased eosinophils in both blood and sputum are associated with respiratory exacerbations and greater hyperinflation (3, 4). Trials aimed at targeting eosinophils in patients with COPD have shown that they play an important yet not completely understood the role in the pathogenesis of COPD (5, 6).